Author: PWeekly

SGLT2 inhibitors were associated with a significant reduction in atrial arrhythmias (AA) and all-cause mortality in patients with cardiac implantable electronic devices (CIED). The results of this real-world study indicate that...

Patients with gout have significantly greater intercritical inflammation and lumbosacral spine monosodium urate crystal (MSU) deposition when compared with those without the condition, and trend toward greater deposition among...

Pegloticase is effective for lowering serum urate patients with uncontrolled or refractory gout, although more than half of patients experience anti-drug antibody development which limits its efficacy.1 Administering pegloticase...

The American Society of Hematology Annual Meeting & Exposition (ASH 2021) Will be held December 11-14, 2021 at the Georgia World Congress Center in Atlanta, as well as virtually. The “premier event in malignant and...

(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Representative Rosa DeLauro (D-CT) for her outstanding support of hematology research at the 2021 ASH Annual Meeting, December 11-14, in Atlanta,...

(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) for his...

MIRROR RCT (NCT03994731) phase III data support the combination of immunosuppression with pegloticase treatment for uncontrolled gout in all patients, raising the response rate from 40-42% to 71%. Physician’s Weekly spoke with...

In the phase IV open-label PROTECT trial of pegloticase therapy (pegylated recombinant uricase) in treating severe gout in renal transplant recipients, 89% of patients achieved the primary endpoint of serum uric acid (sUA) less...